ImmunityBio annual gross margin
2022
2023
2024
2025
ImmunityBio Gross Margin Growth & History (IBRX)
ImmunityBio's gross margin was 99.34% for fiscal 2025.
View full ImmunityBio company overviewImmunityBio annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 99.34% | −0.66 pp |
| 2024 | 2024-12-31 | 100.00% | 0.00 pp |
| 2023 | 2023-12-31 | 100.00% | 0.00 pp |
| 2022 | 2022-12-31 | 100.00% | — |
ImmunityBio quarterly gross margin
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 99.42% | −0.07 pp |
| Q1 2026 | 2026-03-31 | 99.46% | −0.19 pp |
| Q4 2025 | 2025-12-31 | 99.00% | −1.00 pp |
| Q3 2025 | 2025-09-30 | 99.45% | −0.55 pp |
| Q2 2025 | 2025-06-30 | 99.49% | −0.51 pp |
| Q1 2025 | 2025-03-31 | 99.65% | −0.35 pp |
| Q4 2024 | 2024-12-31 | 100.00% | — |
| Q3 2024 | 2024-09-30 | 100.00% | 0.00 pp |
| Q2 2024 | 2024-06-30 | 100.00% | 0.00 pp |
| Q1 2024 | 2024-03-31 | 100.00% | — |
| Q3 2023 | 2023-09-30 | 100.00% | — |
| Q2 2023 | 2023-06-30 | 100.00% | — |
ImmunityBio gross margin trends
Between the periods ended 2022-12-31 and 2025-12-31, ImmunityBio's gross margin decreased from 100.00% to 99.34%, a change of −0.66 percentage points. The latest reported quarter, Q2 2026, shows 99.42%.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review ImmunityBio source filings ↗